Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Nasopharyngeal Carcinoma 12Esophageal Neoplasms 10Esophageal Squamous Cell Carcinoma 8Squamous Cell Carcinoma of Head and Neck 3Carcinoma, Squamous Cell 3Uterine Cervical Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Resectable Lung Non-Small Cell Carcinoma 1Recurrence 1Neoplasms 1Lymphoma 1Immunotherapy Esophagus Cancer 1Hypopharyngeal Neoplasms 1Hepatic Artery Infusion 1Head and Neck Neoplasms 1Central Nervous System Neoplasms 1Advanced Solid Tumor 1Advanced Non-squamous Non-Small-Cell Lung Cancer 1

Interventions

tislelizumab 1nedaplatin 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Immunotherapy Esophagus Cancer × nedaplatin × Clear all
NCT05515315 2024-02-07

Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma

Fuzhou General Hospital

Phase 2 Recruiting
93 enrolled
Gastrointestinal

Immunotherapy Esophagus Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡